Airis Pharma Private Limited - Due diligence report

A 360° intelligence report on Airis Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals -…

2013-08-19 Quthbullapur Mandal, Telangana Active Unlisted Active Compliant
Share
Connect MCP
AP Airis Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Airis Pharma — 360° Intelligence Report

Generated from MCA filings & public records
80/100
Trust Score
Low Risk

Airis Pharma is assessed as Low Risk with a Trust Score of 80/100. Airis Pharma is an active private limited indian non-government company incorporated in 2013, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 26 Jul 2026 from the latest processed filings. Airis Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
74/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
45/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 74/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 2 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 45/100
NameDIN / PANDesignationAppointedTenureDIN status
VENKATA BHATTARAM CHANDRA SEKHAR 01234567 Director 01/04/2018 6 yrs Approved
MOHAN REDDY PATALOLLA 01234567 Director 01/04/2018 6 yrs Approved
GANJI KISHORE KUMAR 01234567 Director 01/04/2018 6 yrs Approved
AJOY PAVAN KUMAR KOPPOLU YERAKALIAH 01234567 Director 01/04/2018 6 yrs Approved
GANTLA SHAILAJA 01234567 Director 01/04/2018 6 yrs Approved
SRILALITHA BHATTARAM 01234567 Director 01/04/2018 6 yrs Approved
Suchritha Reddy Patlolla 01234567 Director 01/04/2018 6 yrs Approved
  • 7 directors on the board.
  • GANTLA SHAILAJA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • 3 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2021)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
27 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Net margin improved to 61%.
Operating for 12+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
3 director exits within 2 years.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment90/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view91/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 4 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 15 events
05 Jan 2026
Director appointed
Suchritha Reddy Patlolla (Director)
Director ceased
BHAGWANT REDDY GANTLA
Director ceased
SHANTHAKUMARI GANJI
Director ceased
JAKKAMPUDI VENKATESWARA RAO
21 Jul 2025
Director appointed
VENKATA BHATTARAM CHANDRA SEKHAR (Director)
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
26 Mar 2021
Securities allotted
90323 Equity Shares - 45.16 Lakh raised
08 Jan 2021
Securities allotted
140000 Equity Shares - 70.00 Lakh raised
31 Dec 2020
Director ceased
GANTLA SHAILAJA
Director ceased
SRILALITHA BHATTARAM
24 Oct 2020
Securities allotted
376500 Equity Shares - 1.88 cr raised
21 Sep 2020
Director appointed
GANTLA SHAILAJA (Director)
Director appointed
SRILALITHA BHATTARAM (Director)
03 Sep 2020
Securities allotted
240000 Equity Shares - 1.20 cr raised
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
7 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 27 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Awak Technologies U72900KA2020FTC133183 Bangalore, Karnataka, India
Orchid Scientific & Innovative India Private Limited U29253MH2011PTC215178 Nashik, Maharashtra, India
Smardtv Global Technology Private Limited U32301KA2019FTC123999 Bangalore South, Karnataka, India
Sara Research & Development Centre Private Limited U24110MH1992PTC067660 Navi Mumbai, Maharashtra, India
Asia Seed India Private Limited U01403KA2011PTC059152 Bangalore, Karnataka, India
Monolom India Pharma Private Limited U24303PN2017FTC188118 Pune, Maharashtra, India
Nuwill Research And Innovations Private Limited U74900KA2015PTC079182 Bangalore, Karnataka, India
Sirak Pharmaceuticals Private Limited U24232TG2008PTC057045 Hyderabad, Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Airis Pharma before audits and certifications: compliance score 74/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Airis Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Airis Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Airis Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Airis Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Airis Pharma an active company?

Airis Pharma has MCA status “Active” with a compliance score of 74/100 (Moderate).

Is Airis Pharma financially healthy?

Airis Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Airis Pharma?

Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Airis Pharma?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 7 active director(s) are on record.

Does Airis Pharma have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Airis Pharma up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 74/100 (Moderate).

Is it risky to lend to Airis Pharma?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.